Screener
Wave Life Sciences WVE Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $558,321 | $638,499 |
| Liabilities, Series A preferred shares, and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $20,362 | $15,700 |
| Accrued expenses and other current liabilities | 18,242 | 26,564 |
| Current portion of deferred revenue | 8,703 | 44,440 |
| Current portion of operating lease liability | 3,508 | 8,361 |
| Total current liabilities | 50,815 | 95,065 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's accounts payable?
- Wave Life Sciences (WVE) reported accounts payable of $20.36M in Q2 2026.
- How has Wave Life Sciences's accounts payable changed year-over-year?
- Wave Life Sciences's accounts payable increased by 38.9% year-over-year, from $14.66M to $20.36M.
- What is the long-term trend for Wave Life Sciences's accounts payable?
- Over 5 years (2020 to 2025), Wave Life Sciences's accounts payable has grown at a 2.6% compound annual growth rate (CAGR), from $13.8M to $15.7M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Wave Life Sciences's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude